Here is the trial registration efficacy outcome:
To evaluate the efficacy of RECCE®327 topical gel on ABSSSI
Assessment method: Wound swab samples to evaluate for bacterial culture.
Timepoint: Wound swabs will be taken at the following timepoints: - Day 1 (baseline), - Day 7 - Day 14
Where is this data? They haven't mentioned cultures or swabs at all. They are suddenly talking about Lipsky and Bates as evidence for meeting their outcomes. Why are they moving the goalposts?
Further, the primary outcome is about bioavailability. Where is this data? Are you really accepting a vague statement about having "met" this endpoint? Was there systemic absorbtion? Is that important? How much? Does it depend on wound type?
As always with Recce, it's what they are not saying that actually tells you all you need to know.
- Forums
- ASX - By Stock
- RCE
- Ann: Positive Phase II Data from Clinical Trial of R327 Gel
RCE
recce pharmaceuticals ltd
Add to My Watchlist
0.65%
!
38.8¢

Ann: Positive Phase II Data from Clinical Trial of R327 Gel, page-20
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
38.8¢ |
Change
0.003(0.65%) |
Mkt cap ! $112.0M |
Open | High | Low | Value | Volume |
38.5¢ | 39.0¢ | 38.0¢ | $4.167K | 10.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 24610 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 49817 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 24610 | 0.380 |
1 | 3248 | 0.375 |
2 | 33181 | 0.365 |
2 | 71806 | 0.360 |
2 | 85000 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 49817 | 1 |
0.400 | 23104 | 2 |
0.410 | 25471 | 1 |
0.435 | 5115 | 1 |
0.440 | 8669 | 2 |
Last trade - 15.44pm 31/07/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |